| [1] |
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015，136(5):E359-E386.
|
| [2] |
Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017[J]. Ann Oncol, 2017，28(8):1700-1712.
|
| [3] |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100，000 women in 123 randomised trials[J]. Lancet, 2012，379(9814):432-444.
|
| [4] |
Mook S, Van’t Veer LJ, Rutgers EJ, et al. Individualization of therapy using Mammaprint: from development to the MINDACT Trial[J]. Cancer Genomics Proteomics, 2007，4(3):147-155.
|
| [5] |
Kwa M, Makris A, Esteva FJ. Clinical utility of gene-expression signatures in early stage breast cancer[J]. Nat Rev Clin Oncol, 2017，14(10):595-610.
|
| [6] |
Audeh W, Blumencranz L, Kling H, et al. Prospective validation of a genomic assay in breast cancer: the 70-gene MammaPrint assay and the MINDACT trial[J]. Acta Med Acad, 2019，48(1):18-34.
|
| [7] |
Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer[J]. N Engl J Med, 2016，375(8):717-729.
|
| [8] |
van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer[J]. Nature, 2002，415(6871):530-536.
|
| [9] |
Buyse M, Loi S, van’t Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer[J]. J Natl Cancer Inst, 2006，98(17):1183-1192.
|
| [10] |
Drukker CA, van Tinteren H, Schmidt MK, et al. Long-term impact of the 70-gene signature on breast cancer outcome[J]. Breast Cancer Res Treat, 2014，143(3):587-592.
|
| [11] |
Esserman LJ, Yau C, Thompson CK, et al. Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades[J]. JAMA Oncol, 2017，3(11):1503-1510.
|
| [12] |
Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures[J]. Breast Cancer Res, 2008，10(4):R65-R65.
|
| [13] |
Bueno-de-Mesquita JM, van Harten WH, Retel VP, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)[J]. Lancet Oncol, 2007，8(12):1079-1087.
|
| [14] |
Drukker CA, Bueno-de-Mesquita JM, Retèl VP, et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study[J]. Int J Cancer, 2013，133(4):929-936.
|
| [15] |
Brandão M, Pondé N, Piccart-Gebhart M. Mammaprint™：a comprehensive review[J]. Future Oncol, 2019，15(2):207-224.
|
| [16] |
Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer[J]. Breast Cancer Res Treat, 2010，119(3):551-558.
|
| [17] |
Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer[J]. N Engl J Med, 2016，375(1):23-34.
|
| [18] |
Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM)[J]. Eur J Cancer, 2017，04(75):284-298.
|
| [19] |
Krop I, Ismaila N, Andre F, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice guideline focused update[J]. J Clin Oncol, 2017，35(24):2838-2847.
|
| [20] |
Giuliano AE, Connolly JL, Edge SB, et al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual[J]. CA Cancer J Clin, 2017，67(4):290-303.
|
| [21] |
Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer[J]. N Engl J Med, 2006，355(6):560-569.
|
| [22] |
Bartlett JM, Bayani J, Marshall A, et al. Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others[J]. J Natl Cancer Inst, 2016，108(9): djw050.
|
| [23] |
Haibe-Kains B, Desmedt C, Piette F, et al. Comparison of prognostic gene expression signatures for breast cancer[J]. BMC Genomics，2008，9:394.
|
| [24] |
Sestak I, Buus R, Cuzick J, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial[J]. JAMA Oncol, 2018，4(4):545-553.
|
| [25] |
Blok EJ, Bastiaannet E, van den Hout WB, et al. Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe[J]. Cancer Treat Rev, 2018，62(1):74-90.
|
| [26] |
Kuijer A, van Bommel AC, Drukker CA, et al. Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study[J]. Genet Med, 2016，18(7):720-726.
|
| [27] |
Wuerstlein R, Kates R, Gluz O, et al. Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study[J]. Breast Cancer Res Treat, 2019，175(2):389-399.
|
| [28] |
Retèl VP, Joore MA, Drukker CA, et al. Prospective cost-effectiveness analysis of genomic profiling in breast cancer[J]. Eur J Cancer, 2013，49(18):3773-3779.
|
| [29] |
Yang M, Rajan S, Issa AM. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model[J]. Cancer, 2012，118(20):5163-5170.
|
| [30] |
Chen E, Tong KB, Malin JL. Cost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancer[J]. Am J Manag Care, 2010，16(12):e333-e342.
|
| [31] |
Seguí MÁ，Crespo C, Cortés J, et al. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective[J]. Expert Rev Pharmacoecon Outcomes Res, 2014，14(6):889-899.
|
| [32] |
Bonastre J, Marguet S, Lueza B, et al. Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer[J]. J Clin Oncol, 2014，32(31):3513-3519.
|
| [33] |
Retèl VP, Linn SC, van Harten WH. Molecular profiling is rather likely to be cost effective[J]. J Clin Oncol, 2015，33(14):1626-1627.
|
| [34] |
Gauchan D, Ramaekers R, Copur SM. Cost-effectiveness of molecular profiling for early breast cancer[J]. J Clin Oncol, 2015，33(14):1627.
|